Bullish indicating open at $55-$60, IPO prices at $37
On Monday, TD Cowen analysts reaffirmed a Buy rating and a $60.00 price target on Vera Therapeutics stock (NASDAQ: VERA), representing significant upside from the current price of $29.57. The analysts noted that Vera’s recent data release surpassed investor expectations, which could positively impact the stock’s performance. According to InvestingPro data, analyst targets for VERA range from $26 to $100, with a strong Buy consensus rating of 1.43.
Vera Therapeutics released topline Phase 3 data for its atacicept treatment in the Origin3 study, showing a statistically significant 42% placebo-adjusted reduction in urine protein-to-creatinine ratio (UPCR) from baseline. This result exceeded investor expectations of 30-34% and the firm’s own expectations of 30-40%. InvestingPro analysis shows the company maintains strong financial flexibility with more cash than debt and a healthy current ratio of 27.68, suggesting adequate resources for continued development.
The analysts highlighted the strong safety and tolerability profile of atacicept. They also mentioned that Vera plans to file a Biologics License Application in the fourth quarter of 2025.
Looking ahead, the analysts anticipate that Vera’s shares could rise significantly, potentially by 50-75%, depending on the upcoming data from rival Otsuka’s Phase 3 study of sibeprenlimab. Otsuka’s results are expected this Friday at the European Renal Association meeting.
The analysts suggested that if Otsuka’s placebo-adjusted UPCR reduction is approximately 7% lower than Vera’s atacicept data, Vera’s stock could experience further gains.
In other recent news, Vera Therapeutics announced positive results from its ORIGIN Phase 3 trial of atacicept, a potential treatment for immunoglobulin A nephropathy (IgAN). The trial met its primary endpoint, achieving a 46% reduction in proteinuria from baseline and a 42% reduction compared to placebo at week 36, with a favorable safety profile. Vera Therapeutics is planning to engage with the FDA for a Biologics License Application for accelerated approval, aiming for a commercial launch in 2026. Analyst firms have shown optimism, with JPMorgan reiterating an Overweight rating and a $68.00 price target, and Evercore ISI maintaining an Outperform rating with a $75.00 target. Cantor Fitzgerald also maintained its Overweight rating with a $100.00 target, citing the potential of B cell modulators like atacicept in addressing unmet needs in IgAN treatment. Analysts noted the clean data from the ORIGIN study and the potential competitive pressure on other treatments like Otsuka’s sibeprenlimab. The ongoing development and regulatory discussions are being closely monitored by investors and industry experts. Vera Therapeutics’ commitment to advancing IgAN treatment is reflected in its sustained ratings and targets from various analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.